Effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults in West Africa

AIDS

Volumn 26, Issue 8, 2012, Pages 951-957

  Balestre, Eric ^a,b   Eholié, Serge P ^c   Lokossue, Amani ^c   Sow, Papa Salif ^d   Charurat, Man ^e   Minga, Albert ^f,h   Drabo, Joseph ^g   Dabis, François ^a,b   Ekouevi, Didier K ^a,b,h   Thiébaut, Rodolphe ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^d Centre Hospitalier Universitaire Dakar   (Senegal)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f CNTS   (Côte d’Ivoire)

^g Service de Médecine Interne   (Burkina Faso)

^h Programme PAC CI   (Côte d’Ivoire)

Author keywords

age; antiretroviral treatment; HIV AIDS; immunological response; linear mixed models; West Africa

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ADULT; AFRICA; AGE DISTRIBUTION; AGING; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL MODEL; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AFRICA, WESTERN; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84861097755     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283528ad4     Document Type: Article

References (35)

1. Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
2. Seyler C, Anglaret X, Dakoury-Dogbo N, Messou E, Touré S, Danel C, et al. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire. Antivir Ther 2003; 8:385-393.
3. Laurent C, Ngom Gueye NF, Ndour CT, Gueye PM, Diouf M, Diakhaté N, et al. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr 2005; 38:14-17.
4. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: Comparison between lowincome and high-income countries. Lancet 2006; 367:817-824.
5. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in ressource-poor settings: A meta-analysis of the published literature. Clin Infect Dis 2005; 41:217-224.
6. Negin J, Cumming RG. HIV infection in older adults in sub-Saharan Africa: Extrapolating prevalence from existing data. Bull World Health Organ 2010; 88:847-853.
7. Mills EJ, Rammohan A, Awofeso N. Ageing faster with AIDS in Africa. Lancet 2011; 377:1131-1133.
8. Le Moing V, Chêne G, Carrieri MP, Besnier JM, Masquelier B, Salamon R, et al. Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors. J Acquir Immune Defic Syndr 2001; 27:372-376.
9. Grabar S, Kousignian I, Sobel A, Le Bras P, Gasnault J, Enel P, et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS 2004; 18:2029-2038.
10. Nogueras M, Navarro G, Antón E, Sala M, Cervantes M, Amengual M, et al. Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more. BMC Infect Dis 2006; 6:159.
11. Yamashita TE, Phair JP, Munoz A, Margolick JB, Detels R, O'Brien SJ, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001; 15:735-746.
12. Viard JP, Mocroft A, Chiesi A, Kirk O, Røge B, Panos G, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: Evidence from the EuroSIDA study. J Infect Dis 2001; 183:1290-1294.
13. Gandhi RT, Spritzler J, Chan E, Asmuth DM, Rodriguez B, Merigan TC, et al. Effect of baseline-and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: Results from ACTG 384. J Acquir Immune Defic Syndr 2006; 42:426-434.
14. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: The Swiss HIV Cohort Study. Arch Intern Med 2003; 163:2187-2195.
15. Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17:1907-1915.
16. Florence E, Lundgren J, Dreezen C, Fisher M, Kirk O, Blaxhult A, et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the Euro-SIDA study. HIV Med 2003; 4:255-262.
17. Marimoutou C, Chêne G, Mercié P, Neau D, Farbos S, Morlat P, et al. Prognostic factors of combined viral load and CD4R cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998. J Acquir Immune Defic Syndr 2001; 27:161-167.
18. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group. Response to combination antiretroviral therapy: Variation by age. AIDS 2008; 22:1463-1473.
19. Althoff KN, Justice AC, Gange SJ, Deeks SG, Saag MS, Silverberg MJ, et al. Virologic and immunologic response to HAART, by age and regimen class. AIDS 2010; 24:2469-2479.
20. Cohen Stuart J, Hamann D, Borleffs J, Roos M, Miedema F, Boucher C, et al. Reconstitution of naive T cells during antiretroviral treatment of HIV-infected adults is dependent on age. AIDS 2002; 16:2263-2266.
21. Bains I, Thiébaut R, Yates AJ, Callard R. Quantifying thymic export: Combining models of naive T cell proliferation and TCR excision circle dynamics gives an explicit measure of thymic output. J Immunol 2009; 183:4329-4336.
22. Tumbarello M, Rabagliati R, de Gaetano Donati K, Bertagnolio S, Montuori E, Tamburrini E, et al. Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy. BMC Infect Dis 2004; 4:46.
23. Orlando G, Meraviglia P, Cordier L, Meroni L, Landonio S, Giorgi R, et al. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med 2006; 7:549-557.
24. Rizzardini G, Trabattoni D, Saresella M, Piconi S, Lukwiya M, Declich S, et al. Immune activation in HIV-infected African individuals. Italian-Ugandan AIDS cooperation program. AIDS 1998; 12:2387-2396.
25. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al. T cell activation is associated with lower CD4R T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-1543.
26. Egger M, Ekouevi DK, Williams C, Lyamuya RE, Mukumbi H, Braitstein P, et al. Cohort profile: The international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. Int J Epidemiol 2011 [Epub ahead of print].
27. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The 'Mortalité 2000 and 2005' surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48:590-598.
28. Mutevedzi PC, Lessells RJ, Rodger AJ, Newell ML. Association of age with mortality and virological and immunological response to antiretroviral therapy in rural South African adults. PLoS One 2011; 6:e21795.
29. Savino W, Dardenne M, Velloso LA, Dayse Silva-Barbosa S. The thymus is a common target in malnutrition and infection. Br J Nutr 2007; Suppl 1:S11-S16.
30. ART-LINC of IeDEA Study Group, Keiser O, Tweya H, Boulle A, Braitstein P, Schecter M, Brinkhof MW, et al. Switching to second-line antiretroviral therapy in resource-limited settings: Comparison of programmes with and without viral load monitoring. AIDS 2009; 23:1867-1874.
31. Le Moing V, Thiébaut R, Chêne G, Sobel A, Massip P, Collin F, et al. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently
32. Egger M, Spycher BD, Sidle J, Weigel R, Geng EH, Fox MP, et al. Correcting mortality for loss to follow-up: A nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. PLoS Med 2011; 8:e1000390.
33. Thiébaut R, Jacqmin-Gadda H, Babiker A, Commenges D; CASCADE Collaboration. Joint modelling of bivariate longitudinal data with informative dropout and left-censoring, with application to the evolution of CD4R cell count and HIV RNA viral load in response to treatment of HIV infection. Stat Med 2005; 24:65-82.
34. De Gruttola V, Tu XM. Modelling progression of CD4-lymphocyte count and its relationship to survival time. Biometrics 1994; 50:1003-1014.
35. Geng EH, Emenyonu N, Bwana MB, Glidden DV, Martin JN. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. J Am Med Assoc 2008; 300:506-507.